skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Lorlatinib (Code C113655)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Lorlatinib

Definition: An orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), with potential antineoplastic activity. Upon administration, lorlatinib binds to and inhibits both ALK and ROS1 kinases. The kinase inhibition leads to disruption of ALK- and ROS1-mediated signaling and eventually inhibits tumor cell growth in ALK- and ROS1-overexpressing tumor cells. In addition, PF-06463922 is able to cross the blood brain barrier. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. ROS1, overexpressed in certain cancer cells, plays a key role in cell growth and survival of cancer cells.

Display Name: Lorlatinib

Label: Lorlatinib

NCI Thesaurus Code: C113655 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C3827088  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-

External Source Codes: 
CAS Registry Number 1454846-35-5 (see NLM ChemIDplus info)
PDQ Closed Trial Search ID 756930
PDQ Open Trial Search ID 756930 (check for NCI PDQ open clinical trial info)
UMLS CUI C3827088

Other Properties:
     Name Value (qualifiers indented underneath)
code C113655
Contributing_Source CTRP
Contributing_Source FDA
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom